pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
229
stories
8h
STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
stat
17h
nChroma halves workforce, BioXcel lets execs go
biospace
1d
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
biospace
1d
AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets
endpoints
1d
9 biotechs will cut at least half their California workforces
biospace
1d
CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
biospace
1d
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
1d
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
biospace
1d
AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discovery
fiercebiotech
1d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
2d
5 acquisitions that forced Big Pharmas to co-parent
biospace
3d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
3d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
4d
Flagship commits £100M to set up AI-focused biotech incubation outpost in London
fiercebiotech
6d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
6d
Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech
endpoints
7d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
7d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
7d
Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
biospace
8d
10 companies hiring in New Jersey
biospace
9d
Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
biospace
9d
Delix raises $100M to advance at-home psychedelic without hallucinatory effects
biospace
10d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
10d
J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
biospace
11d
With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
biospace
13d
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
biospace
14d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
15d
The top 12 companies hiring in biopharma now
biospace
15d
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
biospace
15d
AbbVie bets up to $1.47B on Nxera's gut-targeting IBD program
endpoints
← prev
page 1 of 8
next →